A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CONTROLLED TRIAL TOASSESS THE EFFICACY AND SAFETY OF CELLULAR IMMUNOTHERAPY WITH MDR-101 FOR INDUCTIONOF IMMUNE TOLERANCE IN RECIPIENTS OF HLA-MATCHED, LIVING DONOR KIDNEY TRANSPLANTS

Project: Research project

Project Details

Description

A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CELLULAR IMMUNOTHERAPY WITH MDR-101 FOR INDUCTION OF IMMUNE TOLERANCE IN RECIPIENTS OF HLA-MATCHED, LIVING DONOR KIDNEY TRANSPLANTS
StatusActive
Effective start/end date1/1/18 → 12/31/24

Funding

  • MEDEOR THERAPEUTICS, INC.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint